US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

HORIZON KINETICS MEDICAL ETF

34.66

-0.1046-0.30%

Post-market: 34.760.1046+0.30%16:10 EDT

Volume:188

Turnover:7K

Market Cap:16.29M

PE:- -

High:34.66

Open:34.76

Low:34.66

Close:34.76

52wk High:37.90

52wk Low:30.79

Shares:469.95K

Float Shares:469.95K

Volume Ratio:0.58

T/O Rate:0.04%

Dividend:0.41

Dividend Rate:1.18%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Johnson & Johnson Says New Analysis of Ongoing Phase 3 Trial Data Supports Potential of Multiple Myeloma Combination Therapy

MT Newswires Live

J&J Says New Model-Based Analysis Further Supports the Potential of Tecvayli Plus Darzalex Faspro

Johnson & Johnson: Phase 3 MajesTEC-3 study shows ‘sustained’ disease control

J&J Says MajesTEC-3 Analysis Projects Near-General-Population Mortality Risk for Tecvayli-Darzalex Combo in Early Relapsed Myeloma

J&J - Tecvayli Plus Darzalex Faspro Reduces Multiple Myeloma Progression Risk by 90% Versus Standard of Care

THOMSON REUTERS

New Model-Based Analysis Further Supports the Potential of Tecvayli® (Teclistamab-Cqyv) Plus Darzalex Faspro® (Daratumumab and Hyaluronidase-Fihj) to Redefine Long-Term Survival Expectations in Early Line Relapsed/Refractory Multiple Myeloma

THOMSON REUTERS

J&J - Analysis Estimates 87% of Tecvayli Plus Darzalex Faspro Patients Have Comparable Mortality Risk to General Population

THOMSON REUTERS

Oruka Falls After Reporting Mid-Stage Data for Psoriasis Drug

Wave Life Sciences initiates Phase 2a combination trial of WVE-007

Boyayuan Evidence-Based China Tour: Real-World Pharmacoeconomics Symposium Successfully Concludes in Shenzhen (South China Session)

Kimberly-Clark Offers Remedies in Bid for EU Approval of Kenvue Deal

ETF Market Update (09.23): Oil Geopolitical Premium Fades on Supply Resumption and Diplomatic Thaw, While Innovative Drugs Rally Against the Trend

Novo Nordisk Open to Direct New York Listing, CEO Doustdar Tells FT

Innovative Drug Sector Surges Again on Multiple Tailwinds; On-Site Hot Targets 520880 and 159137 Defy Market Downturn

Hong Kong Stock Market Pulse | CRO Sector Shares Advance as Innovative Drug Contract Orders Grow in Both Volume and Price, Global AI4S Collaborations Poised to Deliver Gains

Medtronic PLC Stock Underperforms Tuesday When Compared to Competitors

New precision medicine venture gives Syngenis added firepower

The West Australian

AbbVie Tells USTR Germany Drug Pricing Reforms Cut Innovative Medicine Value by Nearly 54%

Alkermes ADHD Data Boosts Confidence in ALKS7290, Orexin Pipeline, RBC Says

MT Newswires Live

Eli Lilly Price Target Maintained with a $1250.00/Share by TD Cowen

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/MEDX/news?page=13"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MEDX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MEDX\",,,,,undefined,":{"symbol":"MEDX","market":"US","secType":"STK","nameCN":"HORIZON KINETICS MEDICAL ETF","latestPrice":34.6588,"timestamp":1790971200000,"preClose":34.7634,"halted":0,"volume":188,"hourTrading":{"tag":"盘后","latestPrice":34.7634,"preClose":34.6588,"latestTime":"16:10 EDT","volume":7,"amount":242.6116,"timestamp":1790971804889,"change":0.1046,"changeRate":0.003018,"amplitude":0},"delay":0,"changeRate":-0.0030089116714705068,"floatShares":469946,"shares":469946,"eps":0,"marketStatus":"Market Closed","change":-0.1046,"latestTime":"10-02 16:00:00 EDT","open":34.7634,"high":34.6588,"low":34.6588,"amount":6537,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":34.7634,"sharesOutstanding":569946,"nav":34.72,"aum":16316525.12,"dividendRate":0.011832,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":34.7634,"preClose":34.6588,"latestTime":"16:10 EDT","volume":7,"amount":242.6116,"timestamp":1790971804889,"change":0.1046,"changeRate":0.003018,"amplitude":0},"volumeRatio":0.5802470747599899},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MEDX\",,,,,undefined,":{"symbol":"MEDX","floatShares":469946,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.5802470747599899,"shares":469946,"dividePrice":0.4101,"high":34.6588,"amplitude":0,"preClose":34.7634,"low":34.6588,"week52Low":30.79,"pbRate":"--","week52High":37.9,"institutionHeld":0,"latestPrice":34.6588,"eps":0,"divideRate":0.011832,"volume":188,"delay":0,"ttmEps":0,"open":34.7634,"prevYearClose":33.2024,"prevWeekClose":35.6625,"prevMonthClose":35.2817,"prevQuarterClose":35.2817,"fiveDayClose":35.6625,"twentyDayClose":37.0834,"sixtyDayClose":36.3731},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MEDX\",params:#limit:5,,,undefined,":[{"date":"2025-12-23","symbol":"MEDX","amount":0.4088,"announcedDate":"2025-12-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-23","defaultRemindTime":1766500200000,"name":"HORIZON KINETICS MEDICAL ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-23","currency":"USD","dateTimestamp":1766466000000,"payDate":"2025-12-24"},{"date":"2024-12-24","symbol":"MEDX","amount":0.502335,"announcedDate":"2024-12-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-24","defaultRemindTime":1735050600000,"name":"HORIZON KINETICS MEDICAL ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-26","payableDate":"2024-12-24","currency":"USD","dateTimestamp":1735016400000,"payDate":"2024-12-26"},{"date":"2023-12-27","symbol":"MEDX","amount":1.379798,"announcedDate":"2023-12-26","type":"dividend","market":"US","newRecordDate":"2023-12-28","defaultRemindTime":1703687400000,"name":"HORIZON KINETICS MEDICAL ETF","recordDate":"2023-12-29","payableDate":"2023-12-28","currency":"USD","dateTimestamp":1703653200000,"payDate":"2023-12-29"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MEDX\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-27","recordDate":"2023-12-28","paymentDate":"2023-12-29","value":1.379798,"currency":"USD"},{"executeDate":"2024-12-24","recordDate":"2024-12-24","paymentDate":"2024-12-26","value":0.502335,"currency":"USD"},{"executeDate":"2025-12-23","recordDate":"2025-12-23","paymentDate":"2025-12-24","value":0.4088,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MEDX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MEDX\",pageSize:20,pageCount:13,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669248213","title":"Johnson & Johnson Says New Analysis of Ongoing Phase 3 Trial Data Supports Potential of Multiple Myeloma Combination Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2669248213","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669248213?lang=en_us&edition=fundamental","pubTime":"2026-09-23 23:09","pubTimestamp":1790176197,"startTime":"0","endTime":"0","summary":"Johnson & Johnson (JNJ) said Wednesday that new data from ongoing phase 3 MajesTEC-3 trial has demonstrated sustained disease control and survival rates for relapsed multiple myeloma patients receivin","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BMED","LU1894683264.USD","PJP","LU0820561909.HKD","LU2213496289.HKD","RXL","TRUH","LU0889566641.SGD","LU2750360641.GBP","BK4534","IXJ","XLV","IHE","BK4581","LU0964807845.USD","LU0345769631.USD","LU0689472784.USD","LU2756315664.SGD","LU1674673691.USD","LU1291159041.SGD","LU2756315318.SGD","LU0289739343.SGD","IE00BGHQF631.EUR","BK4504","LU1506573853.SGD","GDOC","FTXH","IE0002141913.USD","LU1629891620.HKD","LU1551013342.USD","LU2602419157.SGD","LU0738911758.USD","FHLC","LU0683600562.USD","LU2430703178.SGD","IE00BVYPNV92.GBP","IE00BDGV0183.EUR","VHT","BK4533","JNJ","LU0234570918.USD","IE00B19Z3B42.SGD","LU0057025933.USD","IYH","SGXZ80539844.SGD","JDOC","IE000M9KFDE8.USD","LU0466842654.USD","LU1162221912.USD","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669548412","title":"J&J Says New Model-Based Analysis Further Supports the Potential of Tecvayli Plus Darzalex Faspro","url":"https://stock-news.laohu8.com/highlight/detail?id=2669548412","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669548412?lang=en_us&edition=fundamental","pubTime":"2026-09-23 22:34","pubTimestamp":1790174066,"startTime":"0","endTime":"0","summary":"BRIEF-J&J Says New Model-Based Analysis Further Supports The Potential Of Tecvayli Plus Darzalex FasproSept 23 (Reuters)-Johnson & JohnsonJNJ.N:NEW MODEL-BASED ANALYSIS FURTHER SUPPORTS THE POTENTIAL ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45F0ND:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0683600562.USD","LU0795875086.SGD","FHLC","BMED","LU0289739699.SGD","IE00B1BXHZ80.USD","LU1585245621.USD","XLV","IE0034235303.USD","MEDX","LU0053666078.USD","LU2471134879.HKD","LU2213496289.HKD","LU0795875169.SGD","IE00BN8TJ469.HKD","IYH","LU1496350502.SGD","IE0002270589.USD","VHT","JDOC","RXL","TRUH","IE0001KFT4U8.USD","SG9999001440.SGD","BK4585","LU0820561909.HKD","LU1066051811.HKD","LU1145028129.USD","IE00B4R5TH58.HKD","JNJ","IXJ","LU0058720904.USD","LU2347655156.SGD","LU0964807845.USD","SG9999001176.USD","IE00B19Z3B42.SGD","IHE","LU0943347566.SGD","SG9999001176.SGD","GDOC","IE0000B7K699.USD","IE000MB6IJN5.SGD","LU2430703178.SGD","FTXH","IE000WAW04H5.SGD","SG9999002232.USD","LU0426417589.USD","LU1228905037.USD","PJP","LU1718418525.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669481042","title":"Johnson & Johnson: Phase 3 MajesTEC-3 study shows ‘sustained’ disease control","url":"https://stock-news.laohu8.com/highlight/detail?id=2669481042","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669481042?lang=en_us&edition=fundamental","pubTime":"2026-09-23 21:56","pubTimestamp":1790171796,"startTime":"0","endTime":"0","summary":"Johnson & Johnson announced new data from the Phase 3 MajesTEC-3 study showing sustained disease control and survival with TECVAYLI plus DARZALEX F...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/johnson-johnson-phase-3-majestec-3-study-shows-sustained-disease-control-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/johnson-johnson-phase-3-majestec-3-study-shows-sustained-disease-control-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMED","LU0683600562.USD","LU1585245621.USD","LU2456880835.USD","LU2129689514.USD","IE000SO60NU8.SGD","LU2347655156.SGD","FHLC","LU1267930813.SGD","LU0070217475.USD","LU1221951046.USD","FTXH","SG9999001440.SGD","XLV","LU0234570918.USD","TRUH","LU0345770993.USD","LU2505996681.GBP","JNJ","IE00BVYPNW00.USD","BK4007","LU1244550577.SGD","LU2430703178.SGD","LU1074936037.SGD","LU0964807845.USD","PJP","IHE","IE000BZT7R73.USD","JDOC","GDOC","LU1778281490.HKD","LU0289739699.SGD","MEDX","IE00BBT3K403.USD","LU0114720955.EUR","IE00BGHQF631.EUR","RXL","SG9999001176.SGD","IXJ","LU1003077747.HKD","IYH","VHT","LU0689472784.USD","LU0511384066.AUD","BK4588","LU1674673691.USD","LU1718418525.SGD","IE000M9KFDE8.USD","IE00BZ1G4Q59.USD","LU1935042991.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669890984","title":"J&J Says MajesTEC-3 Analysis Projects Near-General-Population Mortality Risk for Tecvayli-Darzalex Combo in Early Relapsed Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2669890984","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669890984?lang=en_us&edition=fundamental","pubTime":"2026-09-23 21:47","pubTimestamp":1790171278,"startTime":"0","endTime":"0","summary":"J&J says MajesTEC-3 analysis projects near-general-population mortality risk for Tecvayli-Darzalex combo in early relapsed myelomaJohnson & Johnson released new model-based analyses from the Phase 3 M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDL5QGgq3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0738911758.USD","LU1778281490.HKD","LU0162691827.USD","LU1929549753.HKD","JDOC","LU1061106388.HKD","SG9999001176.SGD","LU2236285917.USD","LU2756315318.SGD","LU1551013342.USD","LU0889566641.SGD","BK4588","IXJ","IHE","BK4581","IE000M9KFDE8.USD","LU0426417589.USD","LU2592432038.USD","LU1551013425.SGD","VHT","BK4585","LU2468319806.SGD","FHLC","XLV","BK4504","SGXZ80539844.SGD","MEDX","PJP","BMED","FTXH","BK4592","IE00BGHQF631.EUR","LU0345770308.USD","IE000WAW04H5.SGD","LU1244550577.SGD","IE000SO60NU8.SGD","LU0234570918.USD","LU1244550221.USD","LU1291159041.SGD","GDOC","TRUH","IE00B3T34201.USD","RXL","LU0795875086.SGD","LU0466842654.USD","JNJ","IYH","LU1032466523.USD","LU0122379950.USD","IE0034235303.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669890634","title":"J&J - Tecvayli Plus Darzalex Faspro Reduces Multiple Myeloma Progression Risk by 90% Versus Standard of Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2669890634","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669890634?lang=en_us&edition=fundamental","pubTime":"2026-09-23 21:47","pubTimestamp":1790171244,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45F0ND:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1585245621.USD","IE00B7SZLL34.SGD","BK4585","LU2129689514.USD","FTXH","LU2487616109.SGD","IE00BLSP4239.USD","IE00B3T34201.USD","MEDX","LU0943347566.SGD","FHLC","IHE","JNJ","PJP","LU1261432733.SGD","IE00BGHQF631.EUR","LU0122379950.USD","BK4534","LU1228905037.USD","IE00BFXG1179.USD","LU2403377893.USD","LU2430703095.HKD","LU0124676726.USD","IE0000B7K699.USD","LU0072461881.USD","BK4532","GDOC","JDOC","LU1221951046.USD","LU1929549753.HKD","BMED","SG9999002224.SGD","LU0289961442.SGD","RXL","IXJ","LU0511384066.AUD","TRUH","LU2456880835.USD","IYH","LU1732800096.USD","VHT","LU0203347892.USD","LU2505996509.AUD","IE000MB6IJN5.SGD","IE000M9KFDE8.USD","XLV","IE000F7OJYX1.SGD","LU0057025933.USD","SG9999002232.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669709489","title":"New Model-Based Analysis Further Supports the Potential of Tecvayli® (Teclistamab-Cqyv) Plus Darzalex Faspro® (Daratumumab and Hyaluronidase-Fihj) to Redefine Long-Term Survival Expectations in Early Line Relapsed/Refractory Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2669709489","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669709489?lang=en_us&edition=fundamental","pubTime":"2026-09-23 21:47","pubTimestamp":1790171244,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45F0ND:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0210528500.USD","VHT","XLV","IHE","LU1244550577.SGD","BK4534","LU0072461881.USD","LU2129689431.USD","LU2430703095.HKD","FHLC","TRUH","LU1066051811.HKD","IE00BVYPNV92.GBP","LU0320765646.SGD","MEDX","LU1732799900.SGD","LU1291159041.SGD","LU1244550494.USD","LU0345769631.USD","SG9999002224.SGD","LU0345770993.USD","BK4581","IE000MB6IJN5.SGD","IE00BJJMRZ35.SGD","IE000BZT7R73.USD","IYH","LU0345770308.USD","JDOC","LU1778281490.HKD","BK4007","RXL","BK4568","LU0114720955.EUR","LU0162691827.USD","IE000F7OJYX1.SGD","LU0203345920.USD","BMED","PJP","LU1983299246.USD","LU1228905037.USD","LU0985320562.USD","IE00B4R5TH58.HKD","IXJ","JNJ","LU1894683348.USD","FTXH","LU2505996681.GBP","BK4550","GDOC","LU1145028129.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669489068","title":"J&J - Analysis Estimates 87% of Tecvayli Plus Darzalex Faspro Patients Have Comparable Mortality Risk to General Population","url":"https://stock-news.laohu8.com/highlight/detail?id=2669489068","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669489068?lang=en_us&edition=fundamental","pubTime":"2026-09-23 21:47","pubTimestamp":1790171244,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45F0ND:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["JNJ","LU0203347892.USD","LU0432979614.USD","LU2756315318.SGD","LU0787776722.HKD","IYH","XLV","LU0122379950.USD","IE00BLSP4239.USD","LU1244550577.SGD","IHE","LU0511384066.AUD","BK4588","LU0943347566.SGD","IE00BN8TJ469.HKD","LU2403377893.USD","RXL","TRUH","FTXH","IXJ","LU0820561909.HKD","LU1196500208.SGD","LU1935042991.SGD","LU0795875086.SGD","LU1032466523.USD","LU0882574055.USD","PJP","IE000F7OJYX1.SGD","BMED","LU2756315664.SGD","MEDX","IE00B3T34201.USD","LU1674673428.USD","LU1162221912.USD","LU2213496289.HKD","BK4592","LU1023059063.AUD","LU2089984988.USD","LU0203345920.USD","LU2129689514.USD","VHT","LU0640476718.USD","LU0289739343.SGD","JDOC","LU2430703178.SGD","GDOC","LU1914381329.SGD","LU0689626769.HKD","FHLC","LU2347655156.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669486848","title":"Oruka Falls After Reporting Mid-Stage Data for Psoriasis Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2669486848","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669486848?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:47","pubTimestamp":1790167639,"startTime":"0","endTime":"0","summary":"BUZZ-Oruka falls after reporting mid-stage data for psoriasis drug** Shares of drug developer Oruka TherapeuticsORKA.Ofall 3.8% to $91 premarket** Co says its experimental drug ORKA-001 showed continu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nL4N45F0US:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","IE00B4R5TH58.HKD","LU0203347892.USD","LU0234570918.USD","LU0965509283.SGD","LU1839511570.USD","LU1551013425.SGD","ORKA","TRUH","LU0320765992.SGD","LU1236620750.USD","IE00BFTCPJ56.SGD","IE00BLSP4452.SGD","AGNG","LU1934455194.USD","LU1093756325.SGD","LU0320765646.SGD","IE00BBT3K403.USD","LU1670627923.USD","RXL","LU1983299246.USD","VHT","FTXH","LU1244550577.SGD","IYH","BK4550","IE0002141913.USD","LU0234572021.USD","IXJ","LU1057294990.SGD","LU2089984988.USD","LU0029864427.USD","MEDX","LU0058720904.USD","LU1934455863.HKD","PJP","LU1061106388.HKD","LU0545039389.USD","PPH","IE00B3PB1722.GBP","IE000MB6IJN5.SGD","BK4581","LU0170899867.USD","LU2237443465.HKD","LU0868494708.USD","FHLC","GLAM","XLV","JDOC","ABBV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669882944","title":"Wave Life Sciences initiates Phase 2a combination trial of WVE-007","url":"https://stock-news.laohu8.com/highlight/detail?id=2669882944","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669882944?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:35","pubTimestamp":1790163326,"startTime":"0","endTime":"0","summary":"Wave Life Sciences (WVE) announced the initiation of its Phase 2a clinical trial evaluating WVE-007, an investigational GalNAc-siRNA, in combinatio...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/wave-life-sciences-initiates-phase-2a-combination-trial-of-wve-007-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/wave-life-sciences-initiates-phase-2a-combination-trial-of-wve-007-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","WVE","NVIB","BK4007","HYLG","MEDX","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124603429","title":"Boyayuan Evidence-Based China Tour: Real-World Pharmacoeconomics Symposium Successfully Concludes in Shenzhen (South China Session)","url":"https://stock-news.laohu8.com/highlight/detail?id=1124603429","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124603429?lang=en_us&edition=fundamental","pubTime":"2026-09-23 17:51","pubTimestamp":1790157060,"startTime":"0","endTime":"0","summary":"On September 22, the fourth stop of the national roadshow series, the South China special session on \"Real-World Pharmacoeconomics Research,\" was successfully held at the Conference Center of...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","MEDX","RCT","BK4159"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669104698","title":"Kimberly-Clark Offers Remedies in Bid for EU Approval of Kenvue Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2669104698","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669104698?lang=en_us&edition=fundamental","pubTime":"2026-09-23 17:32","pubTimestamp":1790155921,"startTime":"0","endTime":"0","summary":"Kimberly-Clark offers remedies in bid for EU approval of Kenvue dealBRUSSELS, Sept 23 (Reuters)-Kimberly-ClarkKMB.Ohas offered concessions to address EU antitrust concerns about its $40 billion bid fo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nL8N45A15Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","RXL","LU1221951046.USD","LU2592432038.USD","JDOC","LU2505996509.AUD","FHLC","IHE","LU1732799900.SGD","FTXH","PJP","IE00BLSP4452.SGD","LU1732800096.USD","LU2129689605.HKD","LU2750360641.GBP","LU2236285917.USD","GDOC","LU1196500208.SGD","IE00BFXG1179.USD","IYH","LU0511384066.AUD","LU1061106388.HKD","LU2487616109.SGD","LU0795875169.SGD","GLAM","IE0002141913.USD","LU1221951129.SGD","BK4550","JNJ","KVUE","LU1674673691.USD","XLV","VHT","KMB","LU0553294199.USD","LU2023250330.USD","LU0122379950.USD","LU0689626769.HKD","BK4568","LU0345769631.USD","LU0289739699.SGD","TRUH","BMED","RSPS","LU0738911758.USD","LU2505996681.GBP","IXJ","SG9999001176.USD","IE0001KFT4U8.USD","LU1066051225.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160389974","title":"ETF Market Update (09.23): Oil Geopolitical Premium Fades on Supply Resumption and Diplomatic Thaw, While Innovative Drugs Rally Against the Trend","url":"https://stock-news.laohu8.com/highlight/detail?id=1160389974","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160389974?lang=en_us&edition=fundamental","pubTime":"2026-09-23 16:58","pubTimestamp":1790153909,"startTime":"0","endTime":"0","summary":"Hong Kong's three major indices weakened collectively on Monday, with tech stocks broadly under pressure and only a few sectors such as mainland property and pharmaceutical biotech managing to rise...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USL","FTXN","DIG","OILT","PXJ","BK1574","MCLmain","DRIP","DWT","BK4550","WTIU","USOI","FLBR","DRLL","OILU","BK4570","DBE","OIH","FAAR","06978","IEO","USE","BZmain","DBO","UCO","UGA","DBC","ERX","MEDX","DUG","BNO","XOP","OILK","GUSH","BK4588","FBZ","SCO","CLmain","DDG","BK1161","BK4585","QMmain","FDN","LNGR","USO","VDE","XES","PXE","159992","IXC","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669177534","title":"Novo Nordisk Open to Direct New York Listing, CEO Doustdar Tells FT","url":"https://stock-news.laohu8.com/highlight/detail?id=2669177534","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669177534?lang=en_us&edition=fundamental","pubTime":"2026-09-23 16:21","pubTimestamp":1790151673,"startTime":"0","endTime":"0","summary":"UPDATE 1-Novo Nordisk open to direct New York listing, CEO Doustdar tells FTSept 23 (Reuters)-Novo NordiskNOVOb.COis open to considering a direct New York Stock Exchange listing, replacing the America","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nL6N45F05A:2","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Novo Nordisk Open to Direct New York Listing, CEO Doustdar Tells FT","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MHIP","LU2471134796.USD","LU2462157665.USD","PPH","IE00BJJMRY28.SGD","VHT","TMED","IE0009355771.USD","OZEM","LU2324357040.USD","ILDR","GDOC","LU1868836591.USD","FTXH","MEDX","NVOH","WDNA","SGXZ99366536.SGD","LU0114720955.EUR","CANC","BK4534","LU1023059063.AUD","LU2168564065.EUR","LU0133085943.USD","LU0345770308.USD","FHLC","LU1623119135.USD","LU0320765992.SGD","PJP","IHE","IXJ","XLV","LLYZ","THNR","NVOX","NVO","LU0354030511.USD","LU2028103732.USD","TRUH","HRTS","JDOC","IYH","MEDI","AGNG","NVOC","IE00BFTCPJ56.SGD","CURE","RXL","LU0640476718.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182951302","title":"Innovative Drug Sector Surges Again on Multiple Tailwinds; On-Site Hot Targets 520880 and 159137 Defy Market Downturn","url":"https://stock-news.laohu8.com/highlight/detail?id=1182951302","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182951302?lang=en_us&edition=fundamental","pubTime":"2026-09-23 14:41","pubTimestamp":1790145669,"startTime":"0","endTime":"0","summary":"On September 23, Hong Kong's pharmaceutical sector resumed its upward momentum after a day of consolidation. Innovative drug development companies saw broad gains, with Immunotech-B leading the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","MEDX","IBBQ","BK1161","LNGR","520880","159137","BK1574","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122623050","title":"Hong Kong Stock Market Pulse | CRO Sector Shares Advance as Innovative Drug Contract Orders Grow in Both Volume and Price, Global AI4S Collaborations Poised to Deliver Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=1122623050","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122623050?lang=en_us&edition=fundamental","pubTime":"2026-09-23 10:40","pubTimestamp":1790131228,"startTime":"0","endTime":"0","summary":"Shares of contract research organization (CRO) companies trading in Hong Kong moved mostly higher during Wednesday's session. As of the time of writing, Joinn Laboratories (China) Co Ltd (06127)...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","BK1574","LNGR","BK4585","159992","KCAI","06978","BK4588","IBBQ","VXUS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669218122","title":"Medtronic PLC Stock Underperforms Tuesday When Compared to Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2669218122","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669218122?lang=en_us&edition=fundamental","pubTime":"2026-09-23 04:37","pubTimestamp":1790109420,"startTime":"0","endTime":"0","summary":"DJ Medtronic PLC Stock Underperforms Tuesday When Compared To CompetitorsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Medtronic PLC  slid 1.07% to $90.77 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index  remaining mostly unchanged at 7,764.64 and the Dow Jones Industrial Average  falling 0.36% to 51,863.69.This was the stock's third consecutive day of losses.Medtronic PLC closed 14.63% short of its 52-week high of $106.33, which the company reached on November 26th.The stock underperformed when compared to some of its competitors Tuesday, as Johnson & Johnson  fell 0.10% to $269.19, Danaher Corp.  rose 2.43% to $221.09, and Abbott Laboratories  rose 0.69% to $103.69.Trading volume  eclipsed its 50-day average volume of 7.8 M.Data source: Dow Jones Market Data, FactSet. Data compiled September 22, 2026.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0210528500.USD","LU0289960550.SGD","SG9999001440.SGD","VHT","LU1791710400.SGD","XLV","IHE","BK4534","LU1061106388.HKD","FHLC","TRUH","LU0683600562.USD","LU1003077747.HKD","MEDX","BK4121","LU0211331839.USD","LU0320765489.SGD","LU2417539215.USD","LU2468319806.SGD","LU0472753341.HKD","LU0390134368.USD","LU0070302665.USD","IYH","IE000BZT7R73.USD","IE00BDGV0183.EUR","JDOC","LU2324357040.USD","RXL","FMED","BMED","IE00BBT3K403.USD","IHI","MDT","LU2125910179.SGD","ABT","LU2471134523.USD","PJP","LU1228905540.USD","DHR","LU1043141123.HKD","TMED","LU0157215616.USD","LU0889566641.SGD","IXJ","JNJ","FTXH","LU2592432038.USD","LU1989771016.USD","LU1366333091.USD","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669175122","title":"New precision medicine venture gives Syngenis added firepower","url":"https://stock-news.laohu8.com/highlight/detail?id=2669175122","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669175122?lang=en_us&edition=fundamental","pubTime":"2026-09-23 00:27","pubTimestamp":1790094446,"startTime":"0","endTime":"0","summary":"Syngenis has joined the renowned Perron Institute and Gene S founders in a precision-medicine venture that puts its integrated DNA and RNA platform to work and opens the door to recurring manufacturing revenue.","market":"hk","thumbnail":"https://images.thewest.com.au/publication/C-22912933/bcb694b9b6d3ad9e7ac40e225d21b3d9b69e7435.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-22912933/bcb694b9b6d3ad9e7ac40e225d21b3d9b69e7435.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/new-precision-medicine-venture-gives-syngenis-added-firepower-c-22912933","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/new-precision-medicine-venture-gives-syngenis-added-firepower-c-22912933","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["SLF.AU","MEDX","BK4588","BMED","JDOC","GNOM","VAS.AU","E200.AU","LFSC","QRE.AU","XKO.AU","WDNA","GDOC","HELX","GNMX","BK4585","BBOZ.AU","IMLC.AU","OZR.AU","EES","XAO.AU","XJO.AU","SYNB","IBB","OZF.AU","VAP.AU","IOZ.AU","IISV.AU","EIGA.AU","DACE.AU","QFN.AU","XT","ADHD","BEAR.AU","GEAR.AU","TMAT","IIGF.AU","ZYAU.AU","STW.AU","GIVE.AU","PBE","HTEC","IDNA","FDIF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669125714","title":"AbbVie Tells USTR Germany Drug Pricing Reforms Cut Innovative Medicine Value by Nearly 54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669125714","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669125714?lang=en_us&edition=fundamental","pubTime":"2026-09-23 00:23","pubTimestamp":1790094183,"startTime":"0","endTime":"0","summary":"AbbVie tells USTR Germany drug pricing reforms cut innovative medicine value by nearly 54%AbbVie testified in a USTR Section 301 probe into Germany, arguing drug pricing and reimbursement policies und","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDLZgjZ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2347655073.USD","IE0002141913.USD","IYH","LU2133065610.SGD","IE00BJJMRZ35.SGD","IE000MB6IJN5.SGD","MEDX","LU2089284900.SGD","XLV","RXL","LU0943347566.SGD","IE00BSNM7G36.USD","LU0859254822.USD","TRUH","JDOC","AGNG","LU0689626769.HKD","LU0057025933.USD","LU2357305700.SGD","LU0912757837.SGD","LU1162221912.USD","LU1267930573.SGD","LU0726765562.USD","LU0122379950.USD","LU0965509283.SGD","VHT","PJP","LU0985320562.USD","LU2023251221.USD","LU0868494617.USD","LU0965509010.AUD","SG9999015945.SGD","LU1934455863.HKD","LU2129689431.USD","FTXH","BK4581","FHLC","LU1037948541.HKD","GLAM","LU0310799852.SGD","PPH","LU1244550221.USD","LU1244550494.USD","ABBV","IXJ","LU1989772840.SGD","IE00B19Z3581.USD","LU2237443465.HKD","LU0882574055.USD","LU0820561818.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669232251","title":"Alkermes ADHD Data Boosts Confidence in ALKS7290, Orexin Pipeline, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2669232251","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669232251?lang=en_us&edition=fundamental","pubTime":"2026-09-22 23:39","pubTimestamp":1790091552,"startTime":"0","endTime":"0","summary":"Alkermes (ALKS) recent attention-deficit/hyperactivity disorder data increased its management's confidence in ALKS7290 and reinforced the potential of its broader \"orexin pipeline,\" RBC Capital Market","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ABVC","BK4139","FBT","MEDX","PSIL","ALKS","IBRN","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669123543","title":"Eli Lilly Price Target Maintained with a $1250.00/Share by TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2669123543","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669123543?lang=en_us&edition=fundamental","pubTime":"2026-09-22 23:11","pubTimestamp":1790089860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LLY/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BK4W5M84.HKD","LU1064131342.USD","LU1057294990.SGD","LU0345770993.USD","LU2456880835.USD","LU0943347566.SGD","LU0354030438.USD","LU0820561909.HKD","LU0234572021.USD","SG9999018865.SGD","GDOC","LU0114720955.EUR","LU0964807845.USD","LU2023250330.USD","LU2746668974.SGD","LU2236285917.USD","LU2361045086.USD","IE00B2B36J28.USD","LU2468319806.SGD","LU0094547139.USD","BK4007","LU0456855351.SGD","SGXZ51526630.SGD","ILDR","LU1868837300.USD","LU0672654240.SGD","LLYZ","LU0466842654.USD","LU2213496289.HKD","LU2361044949.HKD","LU0320765992.SGD","LU2746668461.USD","GB00BDT5M118.USD","LU1093756168.USD","SG9999015952.SGD","BK4581","SG9999018857.SGD","WDNA","LU2471134523.USD","LLY","LU2552382132.HKD","LU1035775433.USD","BK4534","IXJ","LU2361044865.SGD","SG9999014914.USD","LU1061106388.HKD","OZEM","LU2552382215.SGD","LU0708995401.HKD","LU1974910355.USD","IE0005OL40V9.USD","BK4533","LU0266013472.USD","LU0882574055.USD","LU2750360641.GBP","HRTS","LU2168564065.EUR","LU1989771016.USD","SG9999014880.SGD","CURE","LU1868836591.USD","LU1548497426.USD","IE00BFSS8Q28.SGD","LU0096364046.USD","LU0198837287.USD","IE00BKPKM429.USD","LU0385154629.USD","LU2063271972.USD","LU0689472784.USD","LU2089284900.SGD","IE00BN29S564.USD","XLV","LU1291159041.SGD","IE00BFSS7M15.SGD","LU0256863902.USD","AGNG","IE0001KFT4U8.USD","LU2168563687.JPY","LU2756315318.SGD","IE00B1XK9C88.USD","SG9999001176.SGD","IE00BK4W5L77.USD","ELIS","IE0004445239.USD","LU0061475181.USD","BK4588","LU1868836757.USD","LU2023251221.USD","SGXZ81514606.USD","LU0058720904.USD","TMED","LU0353189680.USD","LU2271345857.HKD","LU0225283273.USD","LU0320765059.SGD","SG9999017495.SGD","LU0432979614.USD","LU2461242641.AUD","LU2896262040.SGD","BK4599","LU1551013342.USD","LU1280957306.USD","LU0787776722.HKD","LU0353189763.USD","LU0106261372.USD","LU1629891620.HKD","LU2237438978.USD","IE00BWXC8680.SGD","LU0323591593.USD","IE00B7KXQ091.USD","LU1814569148.SGD","LU1712237335.SGD","SG9999014906.USD","IE00BJJMRY28.SGD","IYH","LU0471298694.HKD","LU2750360997.AUD","LU0823434740.USD","LU0640476718.USD","LU1127390331.HKD","LU2089283258.USD","RXL","SGXZ57979304.SGD","LU0316494557.USD","LU2168564222.USD","LU2237443622.USD","SGXZ31699556.SGD","LU2491050071.SGD","TRUH","LU0109394709.USD","LU2264538146.SGD","LU0210536198.USD","LU0354030511.USD","LU1868836914.USD","LU2089984988.USD","LU2357305700.SGD","LU2462157665.USD","CANC","LU0882574139.USD","LU1979441026.SGD","LU2211815571.USD","IE00B4JS1V06.HKD","IE0004445015.USD","LU1093756325.SGD","LLYX","IE00B775H168.HKD","IE00BKDWB100.SGD","SGXZ99366536.SGD","ELIL","LU1023059063.AUD","LU1983299246.USD","LU1623119135.USD","SG9999001176.USD","SG9999014898.SGD","LU1366192091.USD","LU0889565916.HKD","LU0158827781.USD","LU0174119429.USD","FTXH","LU1069344957.HKD","LU2112291526.USD","MEDI","SG9999013999.USD","LU2756315664.SGD","LU2111349929.HKD","LU0203201768.USD","BK4585","LU0256863811.USD","LU1232071149.USD","LU2491049909.HKD","LU0097036916.USD","LU2471134796.USD","LU0823434583.USD","PPH","LU0109391861.USD","IE00BJLML261.HKD","LU0345770308.USD","LU2237443465.HKD","LU2237443895.HKD","LU0820561818.USD","LU2237443978.SGD","LU1323610961.USD","SG9999015978.USD","IE0002141913.USD","LU2106854487.HKD","LU0823416689.USD","IHE","IE00BJJMRZ35.SGD","LU0471298777.SGD","LU2087625088.SGD","LU2168564495.EUR","MEDX","LU2028103732.USD","LU0203202063.USD","LU0683600562.USD","LLII","LU0158827948.USD","LU2491050154.USD","LU2602419157.SGD","LU1917777945.USD","LU2417539215.USD","LU1720051017.SGD","LU0820562030.AUD","LU1267930730.SGD","JDOC","IE00BJT1NW94.SGD","LU2237443382.USD","LU2265009873.SGD","THNR","LU2168564149.EUR","LU2552382058.USD","LU0122379950.USD","LU1145028129.USD","VHT","LU2237443549.SGD","PJP","LU0133085943.USD","LU0238689110.USD","LU1691799644.USD","IE00BJJMRX11.SGD","LU0417517546.SGD","LU1988902786.USD","LU0289739699.SGD","LU2324357040.USD","SG9999015945.SGD","LU1551013425.SGD","IE0009355771.USD","LU2023250504.SGD","LU2108987350.USD","LU2471134879.HKD","IE00B1BXHZ80.USD","FHLC","IE00B4R5TH58.HKD","LU0079474960.USD","LU1804176565.USD","LU1868837136.USD","LU0006306889.USD","LU2462591350.SGD","MHIP","SG9999015986.USD","LU1720051108.HKD","LU2471134952.CNY","BK4516","IE00BFTCPJ56.SGD","LU2360106947.USD","LU0786609619.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":17,"pageCount":13,"totalSize":339,"code":"91000000","status":"200"}]}}